Vaxxel

Vaxxel is an Innovative viral live-attenuated platform for intranasal vaccine candidates preventing against pneumovirus infections

Vaxxel is active in the pharmaceutical space based in European Union (EU), Europe, Middle East, and Africa (EMEA), founded in 2019.

Its activity falls under pharmaceutical; the profile below is assembled from public directory data.

Its base of operations is European Union (EU), Europe, Middle East, and Africa (EMEA).

Its current recorded stage is Seed.

Recorded headcount: c_00011_00050 employees.

Public records show total funding of about $1.2M.

Sector	Pharmaceutical
Headquarters	European Union (EU), Europe, Middle East, and Africa (EMEA)
Founded	2019
Employees	c_00011_00050
Stage	seed
Total funding	$1,200,000

Website: vaxxel.fr

Emails and contact routes are reserved for registered members.
Create a free account

Browse related